Pulmonx 3Q 2026: Revenue $22.84M, Net income ($8.39M), EPS ($0.19) — 10-Q Summary
Pulmonx reported Q3 2026 revenue of $22.84M, up 6.2% YoY, with net loss narrowing to $8.39M. EPS improved to ($0.19) from ($0.34). Growth driven by Zephyr Valve procedures, offset by lower U.S. volumes and paused China shipments. Nine-month revenue declined 2.5% to $66.2M. China shipments expected to resume in early 2027.
How this was made

The 30-second read
Why it matters
The disclosed numbers are the first public release of Q3 2026 performance, offering fresh data for valuation models.
Market read
Micro‑cap earnings release with modest revenue growth and loss narrowing; limited but immediate relevance for traders holding or shorting LUNG.
What to watch
Potential future upside from resumed China shipments in 2027 and ongoing clinical trial progress.
Background
Pulmonx is a medical‑device company focused on lung‑related therapies. The 10‑Q filing provides its first quarterly financial snapshot for 2026.
Ticker impact
Pulmonx reported Q3 2026 revenue, net loss and EPS figures in its 10‑Q filing.
potential modest upside as the market prices in the loss narrowing
The company remains loss‑making; the improvement is modest and limited to a micro‑cap, so price reaction is likely limited.
Market effects
Limited impact on the broader medical device sector; Pulmonx is a niche player.
No significant regional effect; results pertain to U.S. and limited international markets.
Minimal global relevance given the company's small size.
Counterpoint
Investors may view the continued loss as a red flag despite the narrowing gap.
Key entities
- CompanyPulmonx Corp
Medical‑device firm reporting Q3 2026 results.
